Author Archives: admin


Surgery gives teen opportunity to help other kids with cancer – Houston Chronicle

This is a carousel. Use Next and Previous buttons to navigate

Hallie Barnard, a 12-year old osteosarcoma survivor who has not only persevered through a cancer diagnosis, but she also was born with a rare anemia condition that required a bone marrow transplant. Photographed at MD Anderson on Tuesday, March 29, 2022 in Houston. Barnard is also a patient of Dr. Valerae O. Lewis, chair of orthopaedic oncology at MD Anderson, an internationally recognized surgeon who focuses on limb salvage.

Dr. Valerae O. Lewis, chair of orthopaedic oncology at MD Anderson, is an internationally recognized surgeon who focuses on limb salvage at MD Anderson on Tuesday, March 29, 2022 in Houston.

Hallie Barnard, a 12-year old osteosarcoma survivor who has not only persevered through a cancer diagnosis, but she also was born with a rare anemia condition that required a bone marrow transplant. Photographed at MD Anderson on Tuesday, March 29, 2022 in Houston. Barnard is also a patient of Dr. Valerae O. Lewis, chair of orthopaedic oncology at MD Anderson, an internationally recognized surgeon who focuses on limb salvage.

A bead chain made by Hallie Barnard, a 12-year old osteosarcoma survivor who has not only persevered through a cancer diagnosis, but she also was born with a rare anemia condition that required a bone marrow transplant. Photographed at MD Anderson on Tuesday, March 29, 2022 in Houston. Barnard is also a patient of Dr. Valerae O. Lewis, chair of orthopaedic oncology at MD Anderson, an internationally recognized surgeon who focuses on limb salvage.

Hallie Barnard, a 12-year old osteosarcoma survivor who has not only persevered through a cancer diagnosis, but she also was born with a rare anemia condition that required a bone marrow transplant. Photographed at MD Anderson on Tuesday, March 29, 2022 in Houston. Barnard is also a patient of Dr. Valerae O. Lewis, chair of orthopaedic oncology at MD Anderson, an internationally recognized surgeon who focuses on limb salvage.

Hallie Barnard, a 12-year old osteosarcoma survivor who has not only persevered through a cancer diagnosis, but she also was born with a rare anemia condition that required a bone marrow transplant. Photographed at MD Anderson on Tuesday, March 29, 2022 in Houston. Barnard is also a patient of Dr. Valerae O. Lewis, chair of orthopaedic oncology at MD Anderson, an internationally recognized surgeon who focuses on limb salvage.

Hallie Barnard, a 12-year old osteosarcoma survivor who has not only persevered through a cancer diagnosis, but she also was born with a rare anemia condition that required a bone marrow transplant. Photographed at MD Anderson on Tuesday, March 29, 2022 in Houston. Barnard is also a patient of Dr. Valerae O. Lewis, chair of orthopaedic oncology at MD Anderson, an internationally recognized surgeon who focuses on limb salvage.

Hallie Barnard, a 12-year old osteosarcoma survivor who has not only persevered through a cancer diagnosis, but she also was born with a rare anemia condition that required a bone marrow transplant. Photographed at MD Anderson on Tuesday, March 29, 2022 in Houston. Barnard is also a patient of Dr. Valerae O. Lewis, chair of orthopaedic oncology at MD Anderson, an internationally recognized surgeon who focuses on limb salvage.

Hallie Barnard, a 12-year old osteosarcoma survivor who has not only persevered through a cancer diagnosis, but she also was born with a rare anemia condition that required a bone marrow transplant. Photographed at MD Anderson on Tuesday, March 29, 2022 in Houston. Barnard is also a patient of Dr. Valerae O. Lewis, chair of orthopaedic oncology at MD Anderson, an internationally recognized surgeon who focuses on limb salvage.

Dr. Valerae O. Lewis, chair of orthopaedic oncology at MD Anderson, is an internationally recognized surgeon who focuses on limb salvage at MD Anderson on Tuesday, March 29, 2022 in Houston.

For every procedure Hallie Barnard has undergone at MD Anderson, she receives a bead. The yellow ones symbolize each night in the hospital. The ones that glow in the dark represent radiology appointments.

Theyre for every poke, every wound cleaning, every physical therapy appointment, the 13-year-old said.

MD Anderson launched its Beads of Courage program in 2008 so young patients could document their journeys through cancer treatment. Collecting colorful strings of beads also provides some incentive to show up at dreaded doctor appointments.

Hallie has more than 350 feet of beads.

They symbolize everything that Ive gone through in the past four years, the Denton resident said.

Still, Hallie is less concerned about her own struggles through osteosarcoma, a cancer that begins in the bones, than she is with shining a light on the challenges other children face.

Every time I show people my beads, it dawns on them that children are going through so much, she said. And there are children with longer beads than I have.

According to the American Childhood Cancer Organization, about 15,780 children are diagnosed with cancer in the U.S. each year.

Their studies indicate 1 in 285 children will be diagnosed with cancer before their 20th birthday and that cancer is the leading cause of death for children between the ages of 4 and 14 in the country.

Children are dying of cancer at astonishing rates, Hallie said.

Regardless, she said, childhood cancer research is underfunded. Less than 4 percent of the federal budget for cancer research is dedicated to its study, according to the Childrens Cancer Research Fund, a national nonprofit.

I dont want any of my friends to die anymore, Hallie said. I want to show them that I am there for them. I am their voice. I can speak for those who cannot speak for themselves.

Hallies Heroes, the nonprofit she started with her parents, Elyse and Jesse Barnard, helps fund childrens cancer research.

But thats not how it began. The organization was founded to inspire individuals to register as bone marrow donors. Because, at the time, Hallie was facing another seemingly insurmountable challenge finding a match for herself.

Hallie was diagnosed with Diamond-Blackfan anemia when she was 13 months old.

Your bone marrow is basically what makes your red blood cells, she said. And with DBA, that fails to happen, Hallie said.

Elyse said her daughter did not seem to be growing normally or hitting milestones at the right time during her first year of life.

Our pediatrician would tell me everything was OK, she said. As a first-time mom, we tend to worry about everything, but I knew that something was wrong.

That fear was validated when Hallie went for her 12-month checkup. A blood test revealed low levels of hemoglobin, and she was admitted to the hospital.

Diagnostics pointed to Diamond-Blackfan anemia but doctors were still skeptical due to the rarity of the disease, Elyse said.

In the end, Hallie had a diagnosis. But treatment options were even more elusive.

Only five to seven babies per million have Diamond-Blackfan anemia, according to St. Judes Research Hospital.

Blood transfusions and steroids can be used to manage symptoms, but both take a toll on the body, Elyse said.

Stem cell transplants offer the only possible cure. The issue is finding a donor.

Theres just a 1 percent chance of finding a match for bone marrow transplants, Hallie said.

Her family began looking and moved from Virginia to Texas, after learning that Dallas had one of the four hospitals in the U.S. specializing in the disorder.

Out of the Barnards search for donors, Hallies Heroes was born.

In the search for her own bone marrow donor, other matches were made. So far, there have been 184 and the organization has inspired more than 8,000 people to join the bone marrow registry.

To its mission, Hallies Heroes added funding for Diamond-Blackfan anemia research and covering medical bills.

Hallie found her own match for a bone marrow transplant when she was 9. The procedure was scheduled the following year, 2018.

She was in the hospital for 60 days, kept in isolation for the duration to protect her fragile immune system, which was wiped out by chemo.

After 100 days, the bone marrow transplant is usually considered fully integrated, Elyse said.

You basically do a happy dance, because you have a new immune system, she said. We thought we were in the clear.

But at 120 days, Hallie had a new symptom.

I started getting horrible pains in my leg, she said. We found a small bump, the size of a mosquito bite.

The growth was right above her left knee. Doctors told her to draw a circle around it to see if it grew.

In a week, it had doubled, Hallie said.

Diagnostics revealed the bump was indeed a tumor.

In March 2019, Hallie was diagnosed with osteosarcoma, a bone cancer that develops most often in children and young adults.

Hallie was presented with a few different choices. She could opt for an amputation or limb salvage surgery to remove diseased bone and replace it with a metal implant or a bone graft, called at allograft, from another person.

We wanted to get a second opinion, Hallie said. Our doctor said, I studied under this amazing woman, Dr. Lewis. Yall should go to MD Anderson.

Dr. Valerae O. Lewis serves as the inaugural chair of orthopedic oncology at the hospital. In fact, she created the Department of Orthopedic Oncology in 2014.

The Barnards made an appointment to see her in mid-April 2019.

Data from MD Anderson shows that between 800 and 900 cases of osteosarcoma are diagnosed annually in the U.S. About half of these are children and teens.

Lewis presented Hallie with three options. You can do an amputation, she began.

Historically, that was the only choice available to remove the tumor completely. But now there are additional options limb-salvaging surgery and rotationplasty, Lewis said.

Limb-salvaging surgery can be performed if the cancer has not metastasized.

Limb-salvage is a great option, because it gives kids the ability to keep their legs, Lewis said. But it does take a toll.

Patients activity levels are restricted and additional operations are needed down the road, probably every 15 to 20 years.

The third option, a rotationplasty, removes the tumor along with the middle part of the leg and the knee. The surgeon then rotates the lower leg 180 degrees before reattaching it to the thigh.

Its like an amputation, but we create a new knee, Lewis said.

Rotationplasty allows patients to be higher functioning. Its easier to walk, Lewis said. You can bike, skate and swim. Everything you need a knee for, you can do.

Hallie chose rotationplasty. Surgery was scheduled for late June 2019, and she had chemo before and after surgery.

She was 11 at the time and had complications while healing, including infections. She needed a wound vacuum for about 11 months. When Hallie finished chemo in 2020 in Fort Worth, her bones had not yet fused.

Then, Dr. Lewis came up with a genius idea, Hallie said.

Lewis inserted a titanium rod into the nonhealing site to help.

Hallie said that Lewis restored her confidence.

Theres a point when a patient gives up. And theres also a point when a doctor gives up. She said that she had not given up on my leg yet, Hallie recalled.

After rotationplasty, a prosthesis is worn, and patients have to relearn how to walk.

Even though the ankle now functions as the knee, it is entirely different from the typical configuration, Lewis said.

The foot fits into the prosthesis, she said. And one needs to remember that it is a functional foot interfacing with the prosthesis.

The toes can provide balance and aid in powering the prosthesis, Lewis added. The plantar surface also allows for bearing weight.

Hallie was at MD Anderson for about seven months, working on both physical and occupational therapy, until she headed back to Denton April 8.

Hallie has progressed nicely and is walking distances without support, Lewis said.

With further physical therapy and continued dedication she anticipates Hallie will be running, skipping and jumping in the future.

Hallies follow-up appointments at MD Anderson are scheduled every three months.

When Hallie was first diagnosed with osteosarcoma, she remembers telling her mother, God put me back in the hospital to help other children.

Now she advocates for both children with cancer and those with Diamond-Blackfan anemia.

At one point, while Hallie was healing from surgery, Elyse and Jesse went to a wall where donors names are displayed on the ninth floor of MD Anderson.

Every day, her dad and I passed the wall, Elsye said. One day, she wanted to see Hallie added to the names.

After changing the bylaws of the nonprofit, Hallies Heroes pledged $50,000 over five years in support of Lewis research in the area of pediatric sarcoma.

Hallie went on the wall in November.

It was really cool to come full circle with that, Elyse said. We were once there as parents, not knowing if our child would survive and seeing all the people donate money so that she could.

Now were giving back, because we want other children to survive, she added.

The funding will make a significant impact, Lewis said, and will go toward researching treatments for pediatric sarcoma.

Hallie is a success story, Lewis said. She is our ambassador and is a cheerleader to other patients. She wants to give back and help other kids like her.

Peyton is a Houston-based freelance writer.

Read more:
Surgery gives teen opportunity to help other kids with cancer - Houston Chronicle

Regenerative Medicine Market to Reach US$ 12.9 Bn by 2028, Increase in Demand for Customized Regenerative Medicine to Drive the Market – BioSpace

Wilmington, Delaware, United States: According to Transparency Market Researchs latest report on the global regenerative medicine market for the historical period 20172018 and forecast period 20212028, increase in demand for customized regenerative medicine is projected to drive the global regenerative medicine market during the forecast period

Rise in Prevalence of Chronic Diseases, Genetic Disorders, and Cancer: Key Driver

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=419

Key Players Increased Investment in Research & Development of Regenerative Medicine

Get COVID-19 Analysis on Regenerative Medicine Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=419

Costly Treatment Associated with Regenerative Medicine

Make an Enquiry before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=419

Regenerative Medicine Market: Competition Landscape

More Trending Reports by Transparency Market Research

Dermal Fillers Market: https://www.transparencymarketresearch.com/dermal-fillers-market.html

Vascular Injury Treatment Market: https://www.transparencymarketresearch.com/vascular-injury-treatment-market.html

Hepatorenal Syndrome Treatment Market: https://www.transparencymarketresearch.com/hepatorenal-syndrome-treatment-market.html

Surgical Glue Market: https://www.transparencymarketresearch.com/surgical-glue-market.html

Ultrasound Gels Market: https://www.transparencymarketresearch.com/ultrasound-gel-market.html

Diabetic Foot Ulcers Treatment Market: https://www.transparencymarketresearch.com/diabetic-foot-ulcers-treatment-market.html

Menopausal Hot Flashes Market: https://www.transparencymarketresearch.com/menopausal-hot-flashes.html

Orthobiologics Market: https://www.transparencymarketresearch.com/orthobiologics-market.html

About Us

Transparency Market Research is a global market intelligence company providing market research reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact Us

Rohit Bhisey

Transparency Market Research Inc.

CORPORATE HEADQUARTER DOWNTOWN,

1000 N. West Street,

Suite 1200, Wilmington, Delaware 19801 USA

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

View post:
Regenerative Medicine Market to Reach US$ 12.9 Bn by 2028, Increase in Demand for Customized Regenerative Medicine to Drive the Market - BioSpace

New Amrita Hospital is all set to open in Faridabad in August this year; 2,400-bed facility will become Indias biggest private hospital – The…

Amrita Hospitals announced on Thursday that its new 2,400-bed campus will soon be open to the public in Faridabad in August this year. During the press conference on Thursday, hospital management announced that the new Amrita Hospital is spread across 133 acres of land in Faridabad and it will be the biggest private sector hospital in India.

This would be the second large-scale Amrita Hospital in India after the iconic 1,200-bed Amrita Hospital in Kochi, Kerala, which was established 25 years ago by the Mata Amritanandamayi Math.

The new hospital is located at Sector 88, Faridabad and it will have a total built-up area of 1 crore sq. ft., including a 14-floor-high tower that will encompass the key medical facilities and patient areas. During the press conference, Swami Nijamritananda Puri, Head, Mata Amritanandamayi Math, Delhi announced that the 81 specialties at the hospital will include eight centers of excellence, such as oncology, cardiac sciences, neurosciences, gastro-sciences, renal sciences, bone diseases and trauma, transplants, and mother and child.

Radiation exposure in the digital era crushing fertility among men

Cancer vanishes from every patients body in drug trial miraculously; Shocked doctors say First time in history

Ramsay Hunt Syndrome: Know the causes, symptoms and treatment

Sharp Sight Eye Hospitals in collaboration with LOGY.AI introduces Indias first AI-based cataract screening solution

The hospital will become operational in stages, with 500 beds opening in August this year. In two years, this number will rise to 750 beds, and further to 1,000 beds in five years. When fully operational, the hospital will have a staff of 10,000 people, including over 800 doctors.

On how the new hospital has incorporated the aspects of pandemic-induced demands, Dr. Sanjeev K Singh, Medical Director, Amrita Hospital, Faridabad told Financial Express.com: We have learned a lot from the pandemic. The construction of the hospital began 5-6 years ago and the learnings from the pandemic also got incorporated along the way. For example, any patient who comes in an emergency gets facilitated in a 40-bed setup. In that set-up, we have a decontaminated area in which anyone who needs to shower will be sent there. We have four negative pressure rooms and if we have any suspected cases of covid or covid-like diseases we can send them to concerned specialists. The mechanism of shifting is also planned and implemented. In all critical care units, there are positive pressure isolation rooms.

The massive facility will also include 534 critical care beds which is the highest in India, the hospital management claims. The hospital campus will also include 64 modular operation theaters, most advanced imaging services, fully automated robotic laboratory, high-precision radiation oncology, most updated nuclear medicine, and state-of-the-art 9 cardiac and interventional cath lab for clinical services. Cutting-edge medical research will be a strong thrust area, with a dedicated research block spread across a 7-floor building totaling 3 lakh sq. ft with exclusive Grade A to D GMP lab with focus on identifying newer diagnostic markers, AI, ML, Bioinformatics etc.

Dr. Singh also told Financial Express.com that they want to integrate all aspects of medical science and bridge the gap between clinicians and scientists.

In Kochi, we have established tissue engineering, a nano-medicine-based cardiac stent, bone growth, and lots more. What we are looking at Faridabad campus is developing something new in stem-cell therapies. We want to create techniques like creating human cells on our own in our GMP labs as generally, we rely on international counterparts for such procedures. Recently, we conducted research in which we found that we can use patient pluripetin stem cells in tumours and it will destroy them. For us, oncology is the big thrust area but other areas will be a focus too. The intent of our research facility will be to make the high-end expensive equipment and treatments cost-effective for the common man. We want to integrate medicine, engineering, biotechnology, and other segments altogether, Dr. Singh told Financial Express.com.

Dr. Singh also said that they have already been awarded the Advanced ICMR Clinical Trial Unit and this will enable them to conduct their trials in the new facility.

Mata Amritanandamayi has allocated a certain amount of seed money to initiate research. On the basis of submitted proposals, things will materialise and start, he added.

Dr. Singh also told Financial Express.com that the new hospital will also be empaneled. There is a process of 3-6 months and then after medical facilities will be available under all panels like ECHS, CGHS and other TPAs, he added.

During the press conference, Dr Singh also informed that the hospital will be among the very few facilities in the country to conduct hand transplants, a specialty pioneered by Amrita Hospital in Kochi. We will also do transplants of liver, kidney, trachea, vocal cords, intestine, heart, lung, pancreas, skin, bone, face and bone marrow, he said.

Training of medical students and doctors will be a strong focus area. The hospital will have state-of-the-art robotics, haptic, surgical-medical simulation centre spread across 4 floors and 1.5 lakh sq. ft area, the biggest such learning & development facility for doctors in the country. The facility will also host a medical college and the countrys biggest allied health sciences campus, he stated.

Moreover, the management also informed that ultra-modern Amrita Hospital at Faridabad would be one of Indias largest green-building healthcare projects with a low carbon footprint. It is an end-to-end paperless facility, with zero waste discharge.

There is also a helipad on the campus for swift transport of patients and a 498-room guest house where attendants accompanying the patients can stay, they said.

Original post:
New Amrita Hospital is all set to open in Faridabad in August this year; 2,400-bed facility will become Indias biggest private hospital - The...

The Stem Cell Transplant Process – UChicago Medicine

At the University of Chicago Medicine, our transplant team works side-by-side with the patient, family and referring physician before, during and after transplantation to ensure the best possible outcome. The transplant process differs from patient to patient, but generally includes:

Most patients undergoing stem cell transplantation are cared for in our dedicated unit for approximately one week before and two to three weeks after the procedure. Select patients may receive outpatient stem cell transplant care in specially designed treatment rooms within the unit. The same physicians and nurses who provide inpatient care provide outpatient care.

The stem cell transplant unit is located on the top floor of the Center for Care and Discovery and features state-of-the-art technology and thoughtful amenities:

Our stem cell transplant physicians are members of the nationally renowned UChicago Medicine Comprehensive Cancer Center,one of only two National Cancer Institute (NCI)-designated Comprehensive Cancer Centers in Chicago. It is through the Cancer Center that we participate in clinical trials of emerging therapies. In addition, we are active participants in the Alliance for Clinical Trials in Oncology and the Blood and Marrow Transplant Clinical Trials Network. Involvement in these vital research organizations gives our patients access to the most novel and exciting treatments available.

Our stem cell transplant program laboratory is specially equipped to handle all of the blood and stem cell preparation necessary for transplant, including apheresis (separation and collection of stem cells from the blood) and cryopreservation (freezing of stem cells for future use).

Leading-edge technologies in the laboratory enable us to perform complex procedures that help improve transplant outcomes. These procedures include purging of cancerous cells and purifying donor stem cells to minimize graft-versus-host disease (a serious side effect related to the use of donor cells for transplant).

Read more here:
The Stem Cell Transplant Process - UChicago Medicine

Mesenchymal Stem Cell Secretome: Toward Cell-Free Therapeutic …

Earlier research primarily attributed the effects of mesenchymal stem cell (MSC) therapies to their capacity for local engrafting and differentiating into multiple tissue types. However, recent studies have revealed that implanted cells do not survive for long, and that the benefits of MSC therapy could be due to the vast array of bioactive factors they produce, which play an important role in the regulation of key biologic processes. Secretome derivatives, such as conditioned media or exosomes, may present considerable advantages over cells for manufacturing, storage, handling, product shelf life and their potential as a ready-to-go biologic product. Nevertheless, regulatory requirements for manufacturing and quality control will be necessary to establish the safety and efficacy profile of these products. Among MSCs, human uterine cervical stem cells (hUCESCs) may be a good candidate for obtaining secretome-derived products. hUCESCs are obtained by Pap cervical smear, which is a less invasive and painful method than those used for obtaining other MSCs (for example, from bone marrow or adipose tissue). Moreover, due to easy isolation and a high proliferative rate, it is possible to obtain large amounts of hUCESCs or secretome-derived products for research and clinical use.

Keywords: adipose-derived stem cells; bone marrow mesenchymal stem cells; conditioned media; exosomes; hUCESCs; mesenchymal stem cells; uterine cervical stem cells.

Go here to read the rest:
Mesenchymal Stem Cell Secretome: Toward Cell-Free Therapeutic ...

Asymmetrex’s Kinetic Stem Cell (KSC) Counting Technology Is Featured in the Parent’s Guide to Cord Blood Foundation June Newsletter – 69News WFMZ-TV

The Parent's Guide to Cord Blood Foundation's monthly newsletter reports on research and development of medical treatments using blood and tissues from human umbilical cords in language that is accessible to parents of children receiving or considering such treatments. The June 14 issue of the newsletter features a graphical presentation of stem cell biotechnology company Asymmetrex's KSC technology, which can provide, for the first time, the dosage of the therapeutic stem cells in umbilical cord blood and tissues.

BOSTON, June 15, 2022 /PRNewswire-PRWeb/ -- The Parent's Guide to Cord Blood Foundation is well known for its excellence in advocacy and education to support parents negotiating medical treatments for their children that involve umbilical cord blood and tissues. The Parent's Guide monthly newsletter has a goal of presenting new advances in umbilical cord medical research and treatments in terms that are accessible by parents and others who are not experts. The June 2022 issue, published June 14, provides a graphical presentation of stem cell biotechnology company Asymmetrex's technology that provides the dose of therapeutic umbilical cord stem cells for the first time.

Determining the dosage of therapeutic tissue stem cells is a long-standing unmet need for all tissue stem cell therapies. More commonly mis-called "adult stem cells," tissue stem cells include stem cells found in adults, children, and birth tissues like the placenta and the umbilical cord. Donor umbilical cords are currently a major focus for sourcing therapeutic tissue stem cells, which are found in both their blood (hematopoietic stem cells) and their walls (mesenchymal stem cells). Whereas the medical potential of cord mesenchymal stem cells is still under investigation, the medical efficacy of cord blood hematopoietic stem cells is well established for use in the treatment of childhood leukemias.

Cord blood treatments for children have a continuing need for a method to determine the dose of the therapeutic stem cells. The Parent's Guide newsletter feature describes the two industry standards for certifying cord blood units, flow cytometry and the colony-forming unit (CFU) test. Although they are currently industry certification requirements, neither of these methods gives the stem cell dose or tells which cord blood units will be effective. By some reports, this deficiency leaves nearly 20% of treated children at risk for death.

This June's article is the Parent's Guide newsletter's second feature on Asymmetrex's tissue stem cell counting technology. The first feature appeared in the January 2019 issue of the newsletter. It related the historical context, envisioned applications, and potential impact of kinetic stem cell (KSC) counting, but did not delve into how the technology worked. The latest feature uses a graphical slide format to illustrate how Asymmetrex applies computational simulation to conventional cell count data to determine the number of tissue stem cells in a sample. Asymmetrex's President and CEO James L. Sherley, M.D., Ph.D. is confident that the newsletter's presentation "will help both non-experts and experts to understand how Asymmetrex counts therapeutic tissue stem cells."

In the intervening 3 years, the company's KSC counting technology has advanced greatly. Just in the previous week, at the Meeting in the Millyard Summit of the Advanced Regenerative Manufacturing Institute, the company announced rapid-counting algorithms that will make stem cell counting sufficiently efficient to be performed routinely for research and medicine. CEO Sherley says that he is looking forward to a future Parent's Guide newsletter reporting the use of KSC counting to identify cord blood units that work all of the time for children, instead of only about 80% of the time as now.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. The company's U.S. and U.K. patent portfolio contains biotechnologies that solve the two main technical problems stem cell-specific quantification and stem cell expansion that have stood in the way of more-effective use of human adult tissue stem cells for regenerative medicine and drug development. Asymmetrex markets kinetic stem cell (KSC) counting, the first technology for determination of the dose and quality of tissue stem cell preparations for use in stem cell transplantation medicine and pre-clinical drug evaluations. Asymmetrex is a member company of the Advanced Regenerative Manufacturing Institute | BioFabUSA (ARMI) and the Massachusetts Biotechnology Council (MassBio).

Media Contact

James L. Sherley, M.D., Ph.D., Asymmetrex LLC, 617-990-6819, jsherley@asymmetrex.com

Twitter, Facebook

SOURCE Asymmetrex LLC

Read this article:
Asymmetrex's Kinetic Stem Cell (KSC) Counting Technology Is Featured in the Parent's Guide to Cord Blood Foundation June Newsletter - 69News WFMZ-TV

Stem Cell Transplant the only curative treatment for Sickle cell Disease – NewsPatrolling

World Sickle Cell Day 2022:

Bangalore, June 16, 2022: There are as many as 2.5 million carrier of the gene (Hemoglobin AS) in India that can lead to sickle cell disease, with more than 1,25,000 actual patients spread across the country, with a much higher incidence in the tribal belt of the country. Sickle cell disease is associated with a significant risk of morbidity and premature mortality, especially among children. While in the west, a child receiving comprehensive care in high-resource settings has an estimated 99% survival into adulthood. However, in India, according to an ICMR study, about 20 per cent of children with sickle disease died by the age of two, and 30 per cent children with Sickle Cell Disease die before they reach adulthood.

Dr. Biju George, Professor & Head, Department of Haematology at CMC Vellore, People with Sickle Cell Disease, may beat a risk of progressive organ damage, impaired quality of life, considerable morbidity in childhood, and risk of premature mortality in adulthood [median survival of 58 years]. Sickle Cell disease patients who are undergoing regular life-long blood transfusions, have the best chance of survival and cure with a blood stem cell transplant. This transplant can come from a sibling or a family member. However, there is only a 30% chance of finding a matched sibling donor in the same family. The remaining 70% patients look for a matching donor through a stem cell registry or donor center- a database of voluntary donors between the age group of 18 to 50 years.

Dr. Govind Eriat Nair, Consultant Hematology Hemato-Oncology and Bone Marrow Transplant Gleneagles Global BGS Hospital, Bengaluru, If there is a fully HLA matched donor in the family, there is a 90-95% chance of cure with higher cure rates in younger children of below 12 years of age. However, due to underrepresentation of Indians in the global donor data pool, patients are unable to find a match on time. Also, the awareness about the disease is less, need of the hour is to raise the social awareness about this disease. Genetic counseling and newborn screening are the way forward. Effects of endogamy, consanguinity and role prenatal counseling needs to be addressed in primary screening.

DKMS BMST Foundation India is a non-profit organization dedicated to the fight against blood cancer and other blood disorders, such as thalassemia and sickle cell disease. The organization aims to give every blood disorder patient in need a second chance at life.

To mark World Sickle Cell Day, Patrick Paul, CEO, DKMS BMST Foundation India said, Sickle cell has variance and only the severe form needs a stem cell transplant. An early transplant can help patient with severe Sickle cell disease from organ damage. With rising cases in India, it is the need of the hour that stem cell transplants are made available to more patients to save lives. But due to the misconceptions and lack of awareness about blood stem cell donation, Indians are highly underrepresented in the global donor pool. This situation can only be changed by recruiting many more potential blood stem cell donors from the Indian ethnicity.

The success of a stem cell transplant depends of donors HLA (Human Leukocyte Antigen) matching the patient. The bodys immune system has proteins known as HLA to distinguish cells that belong to the body from those that do not. DKMS-BMST helps in unrelated donor transplant process which includes enrolling and counselling the donors, get their HLA typing done, facilitate search of the donors and later facilitate the blood stem cell collection and the transplant. So, far DKMS-BMST has registered over 60,000 potential donors and have helped 60 patients with second chance at life.

Register as a potential blood stem cell donor:

Healthy individuals between 18-50 years of age can register at: dkms-bmst.org/register

All it takes is five minutes of your time and a simple 3 step process:

Step 1: Visit the site, fill up an online form and you will receive a DIY swab kit at home.

Step 2: Once you receive the swab kit, fill out the consent form and take a tissue sample from the inside of your cheeks with 3 cotton swabs provided in the kit.

Step 3: Send back your swab sample in the pre-paid envelope provided.

DKMS laboratory will then analyze your tissue type and your details will be available in the global search for blood stem cell donors. If you do come up as a suitable donor, DKMS-BMST will get in touch with you straight away. Once you come up as a match, blood stem cells will be obtained from the bloodstream using a procedure called Peripheral Blood Stem Cell Collection, which is similar to a blood donation wherein only your stem cells are taken. This is a safe, non-surgical outpatient procedure.

See more here:
Stem Cell Transplant the only curative treatment for Sickle cell Disease - NewsPatrolling

VITASPRING BIOMEDICAL CO. LTD. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q) – Marketscreener.com

Management's Discussion and Analysis of Financial Condition and Results of Operations

Caution Regarding Forward-Looking Information

This Quarterly Report on Form 10-Q, including, without limitation, statements containing the words "believes", "anticipates", "expects" and words of similar import, constitute forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Such factors include, among others, the following: international, national and local general economic and market conditions: demographic changes; the ability of the Company to sustain, manage or forecast its growth; the ability of the Company to successfully make and integrate acquisitions; existing government regulations and changes in, or the failure to comply with, government regulations; adverse publicity; competition; fluctuations and difficulty in forecasting operating results; changes in business strategy or development plans; business disruptions; the ability to attract and retain qualified personnel; and other factors referenced in this and previous filings.

Given these uncertainties, readers of this Form 10-Q and investors are cautioned not to place undue reliance on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future events or developments.

VitaSpring Biomedical Co. Ltd., formerly Shemn Corp., was incorporated in Nevada on September 6, 2016. We are a start-up business company. We have been engaged in the business of developing and marketing products that promote wellness and a healthy lifestyle since 2019. A change of 100% of Company's ownership occurred effectively on January 21, 2020. As a result, we changed Company name from Shemn Corp. to VitaSpring Biomedical Co. Ltd. on February 17, 2020.

VitaSpring Biomedical Co., Ltd aims to build a cell medical industry, invest in research and development of stem cell applications in regenerative medicine, establish advanced medical research centers and high standard cell production centers, and provide "GTP" standard stem cell preparations for the development of cellular drugs.

For future business development and medical applications, VitaSpring cooperates with affiliated companies to support the mass production and commercialization of X.msc-related medical projects. Some X.msc-based projects are researches and trials of Investment New Drugs and part of them are related to X.exosome, the critical material in the related skincare products. VitaSpring management also expect X.msc-related medical projects to implement in hospitals from a small scale in the future five years.

On March 30, 2020, VitaSpring filed a Certificate of Amendment to its Articles of Incorporation (the "Articles of Amendment") with the Secretary of State of the State of Nevada effecting a name change of the Company to VitaSpring Biomedical Co. Ltd. (the "Corporate Action"). The Corporate Action and the Amended Articles became effective on April 21, 2020, following compliance with notification requirements of the Financial Industry Regulatory Authority.

Under new management, VitaSpring has completed the transition from patent technology into the know-how in the mass-production process of the purifying and culturing technology in the allogeneic mesenchymal stem cell production from the maternal-part placenta. The subject know-how can effectively and steadily culture more than 20 generations of sub-culture cells, which maintain the same level of activity index and contain the magnification of one thousand exosomes than other MSCs in terms of per ml. Accordingly, VitaSpring is able to build stem cell bank regulated by US FDA to provide the ready-to-use allogeneic mesenchymal stem cell for the emergent allogeneic stem cell transplantation at the cost the patient can afford.

VitaSpring's research team has been awarded the 16th, 17 th, 18 th Taiwan National Innovation Award certificates in 2019, 2020, and 2021 and joined the regenerative medicine flagships of the Ministry of Science and Technology from 2007 to 2020, including research projects for the mechanism of human placenta mesenchymal stem cells in different diseases. It highlights the technological foundation for the future clinical application of X.msc.

Through the development of cell medicine, we became a leading international business group in the fields of regenerative medicine applied to the innovative fields of medicine, preventive health care, beauty, and anti-aging. We do not sell products in a form for use by consumers although we may, in the future, develop products for use by consumers.

We have many unique advantages elevating us to be the best in the industry:

1. Discovery and successful isolation of special mesenchymal stem cells (X.msc)

2. Unlike typical MSCs, X.msc do not promote cancer and tumor growth, and is safe to use for the entire body

3. Homogeneous purification technology

4. Viability of X.msc is 1000 time that of the competitor

5. Able to proliferate and maintain stemness of stem cells to 25+ generations

6. Exclusive composition formula of culture medium

7. The exclusive formula of exosomes have a variety of applications

8. Extensive uses of X.msc

9. Immunomodulation and anti-inflammation effect

We file with the SEC our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to reports to be filed pursuant to Sections 13(a) and 15(d) of the Securities Exchange Act of 1934, as amended. The public may read and copy any materials we file with the SEC at the SEC's Public Reference Room at 100 F Street, NE, Washington, D.C. 20549, on official business days during the hours of 10 a.m. to 3 p.m. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains a website at http://www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.

Our corporate headquarters are located at 400 Spectrum Center Dr. #1620, Irvine, CA 92618. Our telephone number is (949) 202-9235. We maintain a website at http://www.vitaspringbio.com that links to our electronic SEC filings and contains information about our subsidiaries which is not a part of this report. All the above documents are available free of charge on our website as soon as reasonably practicable after filing such material electronically or otherwise furnishing it to the SEC

Results of Operations for the Three months Ended April 30, 2022 Compared to the Three months ended April 30, 2021

Revenue and cost of goods sold

For the Three months ended April 30, 2022 and April 30, 2021 the Company generated total revenue of $1,490,000 and $533,800 from selling products to the customer. The cost of goods sold for the quarter ended April 30, 2022 and April 30, 2021 was $922,000 and $294,000, which represent the cost of raw materials.

Total operating expenses for the quarter ended April 30, 2022 and April 30, 2021 were $224,873 and $60,390. The increase was primarily related to increased selling, general and administrative expenses.

The net income for the quarter ended April 30, 2022 and April 30, 2021 was $276,656 and $235,662, accordingly.

Liquidity and Capital Resources and Cash Requirements

At April 30, 2022, the Company had cash of $79,151. The Company had working capital of $1,823,019.

During the quarter ended April 30, 2022, the Company generated $(28,061) of cash in operating activities.

During the quarter ended April 30, 2022 the Company used no cash in investing activities or financing activities.

We cannot guarantee that we will manage to sell all the shares required. We will attempt to raise the necessary funds to proceed with all phases of our plan of operation. As of the date of this report, the current funds available to the Company will not be sufficient to continue maintaining a reporting status.

Our auditors have issued a "going concern" opinion, meaning that there is substantial doubt we can continue as an on-going business for the next twelve months unless we obtain additional capital. Our only sources for cash at this time are investments by others in this offering, selling our paper dung products and loans from our director. We must raise cash to implement our plan and stay in business.

Management believes that current trends toward lower capital investment in start-up companies pose the most significant challenge to the Company's success over the next year and in future years. Additionally, the Company will have to meet all the financial disclosure and reporting requirements associated with being a publicly reporting company. The Company's management will have to spend additional time on policies and procedures to make sure it is compliant with various regulatory requirements, especially that of Section 404 of the Sarbanes-Oxley Act of 2002. This additional corporate governance time required of management could limit the amount of time management has to implement is business plan and impede the speed of its operations.

Limited operating history; need for additional capital

There is no historical financial information about us upon which to base an evaluation of our performance. We are in a start-up stage of operations and have generated limited revenues since inception. We cannot guarantee that we will be successful in our business operations. Our business is subject to risks inherent in the establishment of a new business enterprise, including limited capital resources and possible cost overruns due to price and cost increases in services and products.

Off-Balance Sheet Arrangements

We do not maintain any off-balance sheet arrangements, transactions, obligations or other relationships with unconsolidated entities that would be expected to have a material current or future effect upon our financial condition or results of operations.

The Company has a retained earnings of $1,093,380 and a negative cash flow from operations amounting to $(28,061) for the three months ended April 30, 2022. The Company had $1,490,000 in revenues for the three months ended April 30, 2022. The Company currently earned profit for the period and is in the process of completing its efforts to establish a stabilized source of revenue sufficient to cover operating costs over an extended period. Therefore, there is still a substantial doubt about the Company's ability to continue as a going concern. Management anticipates that the Company will be dependent, for the near future, on additional investment capital to fund operating expenses. The Company intends to position itself so that it will be able to raise additional funds through the capital markets. In light of management's efforts, there are no assurances that the Company will be successful in this or any of its endeavors or become financially viable and continue as a going concern.

Recent Accounting Pronouncements

In October 2016, the FASB issued ASU 2016-16, Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other than Inventory, which requires the recognition of the income tax consequences of an intra-entity transfer of an asset, other than inventory, when the transfer occurs. ASU 2016-16 is effective for interim and annual periods beginning after December 15, 2018, with early adoption permitted. .

In February 2016, the FASB issued ASU 2016-02, Leases, which will amend current lease accounting to require lessees to recognize (i) a lease liability, which is a lessee's obligation to make lease payments arising from a lease, measured on a discounted basis, and (ii) a right-of-use asset, which is an asset that represents the lessee's right to use, or control the use of, a specified asset for the lease term. ASU 2016-02 does not significantly change lease accounting requirements applicable to lessors; however, certain changes were made to align, where necessary, lessor accounting with the lessee accounting model. This standard will be effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years.

Management has considered all recent accounting pronouncements issued since and their potential effect on our financial statements. The Company's management believes that these recent pronouncements will not have a material effect on the Company's consolidated financial statements.

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company's present or future financial statements.

Edgar Online, source Glimpses

More here:
VITASPRING BIOMEDICAL CO. LTD. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q) - Marketscreener.com

Orthopedic Regenerative Medicine Market To Witness the Highest Growth Globally in Coming Years 2022-2028: Ortho Regenerative Technologies Inc,…

TheGlobal Orthopedic Regenerative MedicineMarket 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028 is a valuable source of insightful data for business strategists. It provides the industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as applicable). The research analysts deliver an elaborate description of the value chain, future roadmaps and its distributor analysis. This Market study offers comprehensive data that enhances the understanding, scope, and application of this report. Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche Orthopedic Regenerative Medicine are aligned with your aims.

(Exclusive Offer: Flat 25% discount on this report)Get Free Sample Copy of this Report:

https://www.reporthive.com/request_sample/3157280?Mode=P3

Top LeadingCompanies/Players: Ortho Regenerative Technologies Inc, Personalized stem cells Inc., Anika Therapeutics Inc., Arthrex Inc., Baxter International Inc., Conmed Corporation, Aziyo Biologics, Curasan Inc., Swiss biomed Orthopedics AG, Octane Medical Inc., Stryker Corporation, Carmell Therapeutics Corporation, Zimmer Holdings, Smith & Nephew plc., NuVasive Inc., and Other.

This report segments the Global Orthopedic Regenerative Medicine Market on the basis of Types are:

Stem Cell Therapy (Allogeneic Bones, Autogeneic Bones, and Bone Grafting)

Plasma Based Therapy

Tissue Engineering (Allograft)

On the basis of Application, the Global Orthopedic Regenerative Medicine Market is segmented into

Osteoarticular Diseases

Rheumatoid Arthritis

Ligament Injuries

Bursitis

Osteoporosis

Region Included are:North America, Europe, Asia Pacific, Oceania, South America, Middle East & Africa

Country Level Break-Up:United States, Canada, Mexico, Brazil, Argentina, Colombia, Chile, South Africa, Nigeria, Tunisia, Morocco, Germany, United Kingdom (UK), the Netherlands, Spain, Italy, Belgium, Austria, Turkey, Russia, France, Poland, Israel, United Arab Emirates, Qatar, Saudi Arabia, China, Japan, Taiwan, South Korea, Singapore, India, Australia and New Zealand etc.

Avail Exclusive Discount on various license types on immediate purchase @

https://www.reporthive.com/3157280/check_discount?Mode=P3

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Orthopedic Regenerative Medicine product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of Orthopedic Regenerative Medicine, with price, sales, revenue and global market share of Orthopedic Regenerative Medicine from 2019 to 2022.

Chapter 3, the Orthopedic Regenerative MedicineOrthopedic Regenerative Medicine competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Orthopedic Regenerative Medicine breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.

Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Orthopedic Regenerative Medicine market forecast, by regions, type and application, with sales and revenue, from 2022 to 2028.

Chapter 12, the key raw materials and key suppliers, and industry chain of Orthopedic Regenerative Medicine.

Chapter 13, 14, and 15, to describe Orthopedic Regenerative Medicine sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Browse Full Report for TOC and Description:

https://www.reporthive.com/Report/3157280/orthopedic-regenerative-medicine-market

The report delivers an in-depth evaluation of the Orthopedic Regenerative Medicine market by highlighting data on different aspects which contains drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing. Additional, it also allows you to do valuable competitor research to get inspiration for marketing the products. When it comes to satisfaction, it is necessary to get definitive idea about what is exactly going in the market. This report exactly provides overall market scenario.

Customization of this Report:This report could be customized to the customers requirements. Please contact our sales professional ([emailprotected]), we will ensure you obtain the report which works for your needs.

Contact US: Report Hive ResearchPhone: +1 312-604-7084 | Email:[emailprotected]

Continue reading here:
Orthopedic Regenerative Medicine Market To Witness the Highest Growth Globally in Coming Years 2022-2028: Ortho Regenerative Technologies Inc,...

Maike Sander named to lead the Max Delbrck Center – EurekAlert

image:Maike Sander has been selected to direct the Max Delbrck Center for Molecular Medicine (MDC). view more

Credit: Peter Himsel / MDC

On November 1, 2022, Prof. Maike Sander will take the reins as Scientific Director and Chair of the Board of the Max Delbrck Center for Molecular Medicine in the Helmholtz Association (MDC). The Supervisory Board of the MDC formally appointed her to the post on Thursday, June 16, 2022. The MDC, which is celebrating its 30th anniversary this year, is one of five Health Centers in the Helmholtz Association of German Research Centers. The internationally renowned researcher and experienced science manager Maike Sander will be succeeding Prof. Thomas Sommer, who has directed the MDC on an interim basis since 2019. That will make Sander the first woman to head one of the Helmholtz Health Centers.

The MDC has distinguished itself as an internationally renowned center for highly innovative biomedical research, says Maike Sander. Work at the MDC lays the foundation for better medicine of the future. The MDC provides on outstanding environment for research and attracts talent from around the globe. I had the opportunity to experience this first-hand as a visiting professor at the MDC. As Scientific Director, my goal will be to further strengthen the MDCs role as a leading biomedical research center and to deepen partnerships with other institutions in Berlin and beyond, so that our discoveries can be rapidly turned into medical innovations. Sander emphasizes that medical innovation needs strong basic science, clinical science and industry partners components that are all part of the vibrant Berlin biomedical ecosystem, she points out. The Berlin region is developing into a flourishing biotech pharma hub and I see the MDC as a principal driver of innovation in this landscape. I very much look forward to working with all stakeholders across Berlin.

Maike Sanders research focuses on identifying novel therapeutic approaches for diabetes. To this end, Sander studies the molecular mechanisms that underlie the formation and function of the different cell types in the pancreas, in particular the insulin-producing beta cells. Her goal is to identify strategies for replacing beta cells in diabetes using beta cells derived from human pluripotent stem cells.

Since 2012, Sander has served as the Director of the Pediatric Diabetes Research Center at the University of California, San Diego (UC San Diego), where she is also a Professor in the Departments of Pediatrics and Cellular & Molecular Medicine. In Berlin, Maike Sander will be appointed as Professor at the Charit Universittsmedizin.

Maike Sander is an outstanding scientist with a track record of innovation in biomedical research, says Bettina Stark-Watzinger, Germanys Federal Minister of Education and Research. I am delighted we have been able to bring her back to Germany after many years in the United States and to win her as the new Scientific Director of the Max Delbrck Center. It demonstrates the attractiveness of Berlin as a hub for biomedical research. As a scientist and administrator, Prof. Sander is the perfect match for the MDC with its mission to improve human health through transformative biomedical research. Also, having a female leader is an important signal. Prof. Sanders appointment represents a significant gain for German research.

Berlins Senator for Higher Education and Research, Health, Long-Term Care and Gender Equality, Ulrike Gote, says: In Prof. Maike Sander, the Max Delbrck Center has gained an internationally renowned scientist as its new Scientific Director. I warmly welcome her to the science and healthcare metropolis Berlin. Prof. Sanders expertise and experience provide the ideal background for future development of the MDC and for increasing the international visibility of the vibrant life sciences community at the MDC and in Berlin. As the senator in charge of higher education, research, and gender equality, I am delighted to see a woman at the helm of a Helmholtz Health Center.

I got to know Maike Sander as an expert in diabetes and stem cells when she was a visiting professor at the MDC, says OtmarD.Wiestler, President of the Helmholtz Association. With her high scientific standing and international experience, she is the ideal person to determine the future direction of the MDC as Scientific Director and Chair of the Board. With Prof. Sander we are gaining an excellent scientist whose expertise will be of tremendous benefit to the Helmholtz Association. A critical focus area is the development of precision medicine approaches. The MDC is at the forefront of advancing research in this important area. I look forward to working with Prof. Sander and to a vivid exchange of ideas.

Maike Sander, a native of Gttingen, is 54 years old. After graduating with a medical degree from the University of Heidelberg Medical School in 1994, she conducted research at the University of California, San Francisco. Before moving to UC San Diego in 2008, she held faculty positions at Hamburg Medical School and the University of California, Irvine. An expert on insulin-producing pancreatic beta cells, she has nearly 30 years of experience in medicine and diabetes research.

Sander is an elected member of the German National Academy of Sciences Leopoldina, the Association of American Physicians, and the American Society of Clinical Investigation. In addition, she is a member of two NIH consortia: The Human Islet Research Network and the NIH Impact of Genomic Variation on Function Consortium, which seeks to define basic mechanisms of gene regulation.

She is a recipient of the Grodsky Award of the Juvenile Diabetes Research Foundation, the 2022 Albert Renold Prize of the European Association for the Study of Diabetes, and the Alexander von Humboldt Foundation Research Award. Since 2019, Sander has been an Einstein Visiting Fellow at the Berlin Institute of Health at Charit (BIH).

30 Years MDC

Sander Laboratory and Publications at University of California, San Diego

German Federal Ministry of Education and Research (BMBF) Division for Press; Social Media; Internet Kapelle-Ufer 1 10117 Berlin +49-(0)30-1857-5050 presse@bmbf.bund.de

Jutta Kramm Head of the Staff Unit Communications Max Delbrck Center for Molecular Medicine in the Helmholtz Association (MDC) +49-(0)30-9406-2140 jutta.kramm@mdc-berlin.de or presse@mdc-berlin.de

The Max Delbrck Center for Molecular Medicine in the Helmholtz Association (MDC) is one of the worlds leading biomedical research institutions. Max Delbrck, a Berlin native, was a Nobel laureate and one of the founders of molecular biology. At the MDCs locations in Berlin-Buch and Mitte, researchers from some 60 countries analyze the human system investigating the biological foundations of life from its most elementary building blocks to systems-wide mechanisms. By understanding what regulates or disrupts the dynamic equilibrium in a cell, an organ, or the entire body, we can prevent diseases, diagnose them earlier, and stop their progression with tailored therapies. Patients should benefit as soon as possible from basic research discoveries. The MDC therefore supports spin-off creation and participates in collaborative networks. It works in close partnership with Charit Universittsmedizin Berlin in the jointly run Experimental and Clinical Research Center (ECRC), the Berlin Institute of Health (BIH) at Charit, and the German Center for Cardiovascular Research (DZHK). Founded in 1992, the MDC today employs 1,600 people and is funded 90 percent by the German federal government and 10 percent by the State of Berlin.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Follow this link:
Maike Sander named to lead the Max Delbrck Center - EurekAlert